Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD). ReadyCell has available CacoReady and CacoGoblet to assay compounds inflammatory properties.
A new drug against malignant cells was found using methods such as High Throughput Screening (HTS) and Caco-2 permeability assay with CacoReady plates.
An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).
Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.
The publication, entitled Daily Intraperitoneal Administration of RGZ Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.
It is well known that food intake changes luminal conditions (e.g. pH, motility, microbiota,…) in the stomach and the small intestine, modifying drugs bioavailability. Food-drug interactions are one of the major challenges for oral-administered drugs, even more so if considering the growing use of food supplements and functional foods.